Cuál es el precio por Revive Therapeutics Ltd. (RVV)

Precio por Revive Therapeutics Ltd. (RVV) es de$0.02201811

Cuál es la capitalización de mercado por Revive Therapeutics Ltd. (RVV)

Capitalización de mercado por Revive Therapeutics Ltd. (RVV) es $9.59M

Ingresos de Revive Therapeutics Ltd. (RVV)

Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.

Año	Ingresos	Cambiar
Not enough data for the provided dates.

Año

Ingresos

Cambiar

Not enough data for the provided dates.

Empresa	Ingresos	Diferencia de ingresos	País
MERCK Kommanditgesellschaft auf Aktien MER.SW	-	-	DE
Merck KGaA MRK.DE	-	-	DE
Takeda Pharmaceutical Company Limited 4502.T	-	-	JP
Galderma Group AG GALD.SW	-	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$6.61B	-	IN

Empresa

Ingresos

Diferencia de ingresos

País